-
Study aim
-
Determining the effectiveness of azithromycin treatment protocol and standard treatment in comparison with standard treatment alone in patients with chronic obstructive pulmonary disease (COPD)
-
Design
-
A controlled, double-blind, placebo, randomized controlled clinical trial is performed on 100 patients. For randomization, the blocking method (quadruple blocks) will be used.
-
Settings and conduct
-
Two-blind study. Patients are first subjected to initial pulmonary examinations to determine the initial values of functional tests. Then, until random allocation, they are placed in the intervention and control groups, and spirometric indices and the rate of improvement and control of the disease are recorded using CAT and MMRC questionnaires.
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria
Diagnosis of COPD by an internal medicine specialist, hospitalization based on the global pioneers of chronic obstructive pulmonary disease (GOLD), stable physical and mental condition of the patient, age 40-70 years, no other chronic diseases such as disease Of orthopedics and locomotion, multiple sclerosis and cancer.
Exclusion criteria
Lack of motivation for the patient to continue cooperation, immune system deficiency (recurrent respiratory infections and worsening of shortness of breath), pneumonia, embolism.
Kidney failure, hearing loss
Existence of concomitant asthma
Complications of azithromycin
Existence of atopy or allergic rhinitis
Cancer
Serious non-pulmonary disease
Liver dysfunction, cholestatic jaundice, infiltration and cosolidation on chest x-ray
Patients with acute exacerbation of COOD are also excluded from the study.
-
Intervention groups
-
Intervention group: Oral azithromycin and standard treatment. Control group: receiving standard treatment alone.
-
Main outcome variables
-
Spirometric parameters; evaluation of recovery and control of COPD using CAT and MMRC questionnaires.